Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Accured Expenses (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Change in Accured Expenses for 12 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 219.16% year-over-year to $1.0 million, compared with a TTM value of $2.3 million through Sep 2025, up 175.28%, and an annual FY2024 reading of -$1.1 million, up 87.72% over the prior year.
  • Change in Accured Expenses was $1.0 million for Q3 2025 at Avalo Therapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.2 million in Q2 2021 and bottomed at -$4.9 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$485736.8, with a median of -$686000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses soared 1314.08% in 2021, then tumbled 726.21% in 2023.
  • Year by year, Change in Accured Expenses stood at $646000.0 in 2021, then tumbled by 175.54% to -$488000.0 in 2022, then tumbled by 96.72% to -$960000.0 in 2023, then surged by 204.06% to $999000.0 in 2024, then grew by 2.1% to $1.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for AVTX at $1.0 million in Q3 2025, $2.0 million in Q2 2025, and -$1.7 million in Q1 2025.